Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis

Completed

Conditions: Anemia, Kidney Disease, Chronic

First Posted Date: 2011-03-07

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 250

Registration Number: NCT01309295

A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: bevacizumab [Avastin]
Drug: RO5323441 + bevacizumab [Avastin]

First Posted Date: 2011-03-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 22

Registration Number: NCT01308684

A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: RO5323441
Drug: sorafenib

First Posted Date: 2011-03-04

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT01308723

A Study of Vemurafenib in Participants With Metastatic Melanoma

Phase 3

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Vemurafenib

First Posted Date: 2011-03-02

Last Posted Date: 2017-12-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3219

Registration Number: NCT01307397

Locations: 🇦🇱
University "Mother Theresa" Hospital Center; Oncology Department, Tirana, Albania
🇦🇷
Hospital Britanico; Oncologia, Buenos Aires, Argentina
🇦🇷
Fundación CIDEA, Buenos Aires, Argentina

and more 277 locations

Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

Phase 2

Completed

Conditions: Spinal Muscular Atrophy Type II
Spinal Muscular Atrophy Type III Non Ambulant

Interventions: Drug: Placebo
Drug: Olesoxime

First Posted Date: 2011-02-24

Last Posted Date: 2016-11-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 165

Registration Number: NCT01302600

Locations: 🇫🇷
Hôpital Raymond Poincaré, Garches, France
🇫🇷
Hôpital Femme-Mère-Enfant, Bron, France
🇩🇪
University of Essen, Essen, Germany

and more 18 locations

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2011-02-23

Last Posted Date: 2016-12-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT01301729

Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection

Completed

Conditions: HIV Infections

First Posted Date: 2011-02-16

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 151

Registration Number: NCT01297127

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Phase 3

Withdrawn

Conditions: Hepatitis C, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]
Drug: ribavirin [Copegus]

First Posted Date: 2011-02-16

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT01296971

A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).

Phase 2

Completed

Conditions: Kidney Transplantation

Interventions: Drug: mycophenolate mofetil
Drug: antibody induction
Drug: Cyclosporine
Drug: corticosteroid

First Posted Date: 2011-02-09

Last Posted Date: 2016-05-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT01292226

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: rituximab [MabThera]

First Posted Date: 2011-02-09

Last Posted Date: 2018-12-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 240

Registration Number: NCT01292603

Locations: 🇧🇷
Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil
🇦🇷
HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina
🇩🇪
Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, Germany

and more 81 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy